NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
Clinical Trials
3 trialsNCT03832673 2021-02-26
PECULIAR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Withdrawn
NCT01685255 2019-03-11
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
Phase 2 Terminated